Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Go‐Won Choi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0001-7815-9834; OpenAlex author ID A5087167771. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2025: 5 papers · 2026: 4 papers

Papers 9

  1. Distinct clinicopathologic features and efficacy of adjuvant therapy in intraductal papillary mucinous carcinoma compared with conventional pancreatic ductal a… Co-author DOI 10.1016/j.suronc.2026.102368↗
  2. ASO Visual Abstract: Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment According to CAP Grading… Co-author DOI 10.1245/s10434-025-18349-8↗
  3. Correction: Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment according to CAP Grading System: … Co-author DOI 10.1245/s10434-026-20624-1↗
  4. Comparison of postoperative survival after neoadjuvant treatment versus upfront surgery in resected pancreatic ductal adenocarcinoma: a propensity score matchi… Co-author DOI 10.4174/astr.2026.111.2.93↗
  5. Metabolic response during preoperative chemotherapy can predict prognosis in pancreatic cancer. Co-author DOI 10.1002/jhbp.12122↗
  6. Long-term oncologic outcomes of robot-assisted pancreaticoduodenectomy versus open pancreaticoduodenectomy for pancreatic cancer. Co-author DOI 10.1007/s00464-025-11833-y↗
  7. Prognostic implications of resection margin status in distal pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2025.04.001↗
  8. Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment according to CAP Grading System: Clinical Use… Co-author DOI 10.1245/s10434-025-18123-w↗
  9. Impact of Nutritional Changes on the Prognosis in Pancreatic Cancer Patients Underwent Curative Surgery After Neoadjuvant Chemotherapy. First author DOI 10.3390/nu17040647↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hye‐Sol Jung · 9 shared papers, 2025–2026 · strength 2.33
  2. Jin‐Young Jang · 9 shared papers, 2025–2026 · strength 2.33
  3. Wooil Kwon · 9 shared papers, 2025–2026 · strength 2.33
  4. Won‐Gun Yun · 8 shared papers, 2025–2026 · strength 2.05
  5. Yoon Soo Chae · 7 shared papers, 2025–2026 · strength 1.82
  6. Younsoo Seo · 7 shared papers, 2025–2026 · strength 1.82
  7. Joon Seong Park · 5 shared papers, 2025–2026 · strength 1.31
  8. Youngmin Han · 2 shared papers, 2025–2026 · strength 0.52
  9. Seulah Park · 2 shared papers, 2025 · strength 0.48
  10. Young‐Jae Cho · 2 shared papers, 2025 · strength 0.47
  11. Wonjun Jang · 1 shared paper, 2026 · strength 0.28
  12. Mirang Lee · 1 shared paper, 2025 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.